Salvaging the forgotten valve: T-TEER as the new frontier in torrential primary TR
4 affiliations
- 1Department of Cardiothoracovascular Medicine, Careggi University Hospital
- 2Cardiac Surgery Unit, Careggi University Hospital
- 3Department of Geriatric and Intensive Care Medicine, Careggi University Hospital
- 4Department of Clinical Experimental Medicine, University of Florence
Abstract
Tricuspid regurgitation (TR) has historically been considered the “forgotten valve disease”, but growing evidence has established its independent prognostic impact and has driven the rapid expansion of transcatheter tricuspid valve interventions. While transcatheter tricuspid edge-to-edge repair (T-TEER) has demonstrated safety and clinical benefit in patients with secondary functional TR, evidence supporting its use in primary TR remains scarce, and surgery continues to represent the standard treatment. However, many patients with primary TR are considered ineligible for surgery because of prohibitive operative risk, creating an important unmet therapeutic need. In this Perspective, we discuss the potential role of T-TEER in selected patients with primary TR through the paradigm of a patient who developed torrential TR following iatrogenic rupture of the septal papillary muscle–chordal apparatus during cardiac device lead extraction. Owing to multiple comorbidities and prohibitive surgical risk, the patient underwent successful transcatheter repair with two PASCAL Ace devices, achieving durable TR reduction and sustained clinical improvement at one-year follow-up. Building on this experience, we review the current evidence supporting transcatheter tricuspid interventions, discuss the anatomical and procedural considerations that may enable T-TEER in selected forms of primary TR, and highlight the limitations of the available literature. We propose that carefully selected anatomical subsets of primary TR may represent an emerging frontier for transcatheter therapies, bridging the gap between guideline-directed management and individualized treatment when surgery is not feasible. Prospective studies are warranted to define patient selection criteria, procedural feasibility, and long-term clinical outcomes.
Related
- Tricuspid Regurgitation, the Once-Forgotten Valve: Current Management Options and Remaining Gaps After the 2025 European Society of Cardiology Guidelines Update
- Primary Mesangial Proliferative Glomerulonephritis: The Forgotten Glomerulopathy.
- Myocardial Perfusion in Patients with Primary Mitral Regurgitation Due to Mitral Valve Prolapse
- Resolution of Lancisi's sign following bicaval TricValve implantation for torrential tricuspid regurgitation: a case report defining a novel bedside marker of haemodynamic recovery.
- Early Mitral Valve Surgery and Survival in Asymptomatic Severe Primary Mitral Regurgitation
BibTeX
@article{carrabba2026salvaging,
title = {{Salvaging the forgotten valve: T-TEER as the new frontier in torrential primary TR}},
author = {Nazario Carrabba and Mattia Alexis Amico and Andrea Taddei and Renato Valenti and Alfredo Giuseppe Cerillo and Pierluigi Stefano},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1939762},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1939762/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Salvaging the forgotten valve: T-TEER as the new frontier in torrential primary TR
AU - Nazario Carrabba
AU - Mattia Alexis Amico
AU - Andrea Taddei
AU - Renato Valenti
AU - Alfredo Giuseppe Cerillo
AU - Pierluigi Stefano
PY - 2026
DA - 2026/10/21
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1939762
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1939762/full
AB - Tricuspid regurgitation (TR) has historically been considered the “forgotten valve disease”, but growing evidence has established its independent prognostic impact and has driven the rapid expansion of transcatheter tricuspid valve interventions. While transcatheter tricuspid edge-to-edge repair (T-TEER) has demonstrated safety and clinical benefit in patients with secondary functional TR, evidence supporting its use in primary TR remains scarce, and surgery continues to represent the standard treatment. However, many patients with primary TR are considered ineligible for surgery because of prohibitive operative risk, creating an important unmet therapeutic need. In this Perspective, we discuss the potential role of T-TEER in selected patients with primary TR through the paradigm of a patient who developed torrential TR following iatrogenic rupture of the septal papillary muscle–chordal apparatus during cardiac device lead extraction. Owing to multiple comorbidities and prohibitive surgical risk, the patient underwent successful transcatheter repair with two PASCAL Ace devices, achieving durable TR reduction and sustained clinical improvement at one-year follow-up. Building on this experience, we review the current evidence supporting transcatheter tricuspid interventions, discuss the anatomical and procedural considerations that may enable T-TEER in selected forms of primary TR, and highlight the limitations of the available literature. We propose that carefully selected anatomical subsets of primary TR may represent an emerging frontier for transcatheter therapies, bridging the gap between guideline-directed management and individualized treatment when surgery is not feasible. Prospective studies are warranted to define patient selection criteria, procedural feasibility, and long-term clinical outcomes.
SN - 2297-055X
ER -